Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Agios Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 11, 2019 / 04:00PM GMT
Release Date Price: €56 (+1.61%)
Chris Shibutani;Andrew Hirsch
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst;Agios

Okay. Let's get a running start. Good morning. My name is Chris Shibutani, I'm a member of the Cowen Biotech Research Group. I am thrilled to present this next company, Agios Pharmaceuticals. We -- and our group always choose talks that we think will perform best throughout the year. In 2019, amongst those small mid-cap names, Agios was my pick. We also identify this company as one of the companies that really is on that cluster of companies that could become the next kind of generation of Genentech 2.0, so to speak. Companies that have some special secret sauce, the ability to take it to that next level. And really, kind of an outlook that can extend beyond to where the company could really grow and become one of the franchise player [within] biotech. We're thrilled to have us, the CFO, Andrew Hirsch; and Chief Scientific Officer, Scott Biller.

Andrew is going to kick off with some comments. Then I'll confuse them with questions shortly. Thanks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot